Search Result

Results for "

B1756

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Apoptosis (9) Autophagy (3) Calcium Channel (1) Caspase (1) Drug Derivative (4) Environmental Pollutants (1) Insecticide (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Mitochondrial Metabolism (3) Monoamine Oxidase (4) NF-κB (1) p38 MAPK (1) Proteasome (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (4) Reference Standards (3) SOD (1) Thyroid Hormone Receptor (2) TNF Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Endocrinology (6) Infection (1) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (15)

By Targets:

Amyloid-β (1)

Apoptosis (9)

Autophagy (3)

Calcium Channel (1)

Caspase (1)

Drug Derivative (4)

Environmental Pollutants (1)

Insecticide (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (1)

Mitochondrial Metabolism (3)

Monoamine Oxidase (4)

NF-κB (1)

p38 MAPK (1)

Proteasome (1)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (3)

SOD (1)

Thyroid Hormone Receptor (2)

TNF Receptor (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (1)

Endocrinology (6)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (5)

Neurological Disease (15)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1756

Rotenone 175+ Cited Publications	Environmental Pollutants Apoptosis Mitochondrial Metabolism Autophagy	Neurological Disease
Rotenone is a mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.

HY-B1756R

Rotenone (Standard)	Reference Standards Mitochondrial Metabolism Autophagy Apoptosis	Neurological Disease Cancer
Rotenone (Standard) is the analytical standard of Rotenone. This product is intended for research and analytical applications. Rotenone is a mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.

HY-B1756S

Rotenone-d3	Isotope-Labeled Compounds Apoptosis Mitochondrial Metabolism Autophagy	Neurological Disease Cancer
Rotenone-d₃ is the deuterium labeled Rotenone (HY-B1756). Rotenone is a mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.

HY-B0886A

Iproniazid 2 Publications Verification	Monoamine Oxidase Apoptosis	Neurological Disease Metabolic Disease Endocrinology
Iproniazid is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity .

HY-B0596

Taltirelin 1 Publications Verification TA-0910	Thyroid Hormone Receptor Apoptosis	Neurological Disease Endocrinology
Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC₅₀ at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca ²⁺ concentration (Ca ²⁺ release) with an EC₅₀ value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .

HY-153898

rTRD01	Amyloid-β	Neurological Disease
rTRD01 is an orally active, specific TDP-43 binder that targets the RRM1 and RRM2 domains of TDP-43. rTRD01 partially disrupts the interaction between TDP-43 and c9orf72 repeat RNA, but does not affect the binding of TDP-43 to canonical binding sequences. rTRD01 exhibits significant neuroprotective effects in zebrafish models, improves motor function and protects against paraquat (a widely used herbicide)-induced neurodegeneration, with no teratogenicity at high concentrations. rTRD01 is not a general antioxidant and cannot counteract Rotenone (HY-B1756)-induced neuronal death. rTRD01 can be used to study amyotrophic lateral sclerosis and other TDP-43 proteinopathies .

HY-B0886

Iproniazid phosphate 2 Publications Verification	Monoamine Oxidase Apoptosis	Neurological Disease Metabolic Disease Endocrinology
Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity .

HY-B0596A

Taltirelin acetate 1 Publications Verification TA-0910 acetate	Thyroid Hormone Receptor Apoptosis	Neurological Disease Endocrinology
Taltirelin acetate (TA-0910) is an acetate form of Taltirelin (TA-0910). Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC₅₀ at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca ²⁺ concentration (Ca ²⁺ release) with an EC₅₀ value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .

HY-155126

LZWL02003	Reactive Oxygen Species (ROS)	Neurological Disease
LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP ⁺-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .

HY-136903

SNJ-1945	Calcium Channel Proteasome Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SNJ-1945 is an orally active Calpain inhibitor that can cross the blood-brain barrier. SNJ-1945 protects rat hearts against cardiac arrest-reperfusion injury by inhibiting the hydrolysis of α-fodrin. SNJ-1945 inhibits VEGF-induced angiogenesis in retinal endothelial cells. SNJ-1945 also protects SH-SY5Y cells from damage induced by MPP+ (HY-W008719) and Rotenone (HY-B1756). SNJ-1945 exhibits anti-inflammatory and neuroprotective activities in a mouse model of multiple sclerosis. SNJ-1945 can be used for the research of cardiovascular, nervous system and inflammatory diseases .

HY-N15190

Sesaminol	Quinone Reductase Keap1-Nrf2 Reactive Oxygen Species (ROS)	Neurological Disease
Sesaminol is an orally active activator for Nrf2-ARE pathway, that promotes the the nuclear translocation of Nrf2 and enhances the NQO1 expression, thereby enhances the cell's defense against oxidative stress. Sesaminol inhibits 6-OHDA (HY-B1081)-induced ROS production and apoptosis in cell SH-SY5Y. Sesaminol exhibits neuroprotective efficacy against Rotenone (HY-B1756)-induced Parkinson's disease .

HY-B0886AR

Iproniazid (Standard)	Reference Standards Monoamine Oxidase Apoptosis	Neurological Disease Metabolic Disease Endocrinology
Iproniazid (Standard) is the analytical standard of Iproniazid (HY-B0886A). This product is intended for research and analytical applications. Iproniazid is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity .

HY-173221

MJ210	NF-κB p38 MAPK Reactive Oxygen Species (ROS)	Neurological Disease
MJ210 is a modulator of the NF-κB and MAPK pathways with oral activity and the ability to penetrate the blood-brain barrier, and it exhibits neuroprotective activity. In vitro, 5 μM of MJ210 can increase the survival rate of SH-SY5Y cells treated with Rotenone (HY-B1756) to 81.9% and reduce the level of ROS, etc. In vivo, 5 mg/kg of MJ210 can improve the motor impairment in a rat model of Parkinson's disease. MJ210 can be used in the research of neurological diseases, such as Parkinson's disease .

HY-N11731

Rotenonone	Insecticide Drug Derivative	Infection
Rotenonone is a derivative of Rotenone (HY-B1756), with a LD₅₀ of 0.68 μg/g against larvae of Spodoptera litura .

HY-N11730

6',7'-Epoxyrotenone	Drug Derivative	Others
6',7'-Epoxyrotenone is a derivative and photodegradation product of Rotenone (HY-B1756), with an acute intraperitoneal LD₅₀ of 7.2 mg/kg in mice .

HY-N18055

Derritol	Drug Derivative	Others
Derritol is a rotenone degradation product formed by the loss of C-6 and C-6a carbons from Rotenone (HY-B1756) .

HY-N11732

O-Demethylrotenone	Drug Derivative	Inflammation/Immunology
O-Demethylrotenone is a rotenone (HY-B1756) derivative and a photodegradation product of rotenone that induces acute intraperitoneal toxicity. The acute intraperitoneal LD₅₀ of O-Demethylrotenone in Mus musculus is 8.0 mg/kg .

HY-B0886R

Iproniazid phosphate (Standard)	Reference Standards Monoamine Oxidase Apoptosis	Neurological Disease Metabolic Disease Endocrinology
Iproniazid (phosphate) (Standard) is the analytical standard of Iproniazid phosphate (HY-B0886). This product is intended for research and analytical applications. Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity .

HY-N7773

Hibiscetin	TNF Receptor Interleukin Related Caspase SOD	Neurological Disease Metabolic Disease
Hibiscetin is an orally active anti-inflammatory, antioxidant, antihyperglycemic, hypolipidemic, hepatoprotective and neuroprotective agent. Hibiscetin reduces the levels of TNF-α, IL-1β and IL-6. Hibiscetin inhibits lipid peroxidation, reduces MDA levels, and induces the activities of antioxidant enzymes CAT, GSH and SOD. Hibiscetin lowers blood glucose, reverses reduced insulin levels, regulates adipokine levels, and reduces elevated AST and ALT levels. Hibiscetin alleviates Rotenone (HY-B1756)-induced akinesia and catalepsy, normalizes neurotransmitter levels, and modulates the activities of activated caspase 3 and BDNF. Hibiscetin can be used in the research of type 2 diabetes, Parkinson's disease and Huntington's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure